stockrowMerck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −130.7%
- Free cash flow
- +77.0%
- Total debt
- +50.4%
Quarter to September 2026, against a year earlier
Follow MRK
Alert me
Merck & Co., Inc. (MRK) Shares outstanding
Merck & Co., Inc.'s shares outstanding at the end of fiscal 2025 was $2.5B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $2.5B. Over the past ten years it has ranged from $2.5B (fiscal 2025) to $2.8B (fiscal 2015) — the current reading is the lowest in ten years. Merck & Co., Inc. ranks 3rd of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $2.5B | (1.34%) |
| FY2024 | $2.5B | (0.24%) |
| FY2023 | $2.5B | 0.20% |
| FY2022 | $2.5B | 0.16% |
| FY2021 | $2.5B | (0.12%) |
| FY2020 | $2.5B | (1.51%) |
| FY2019 | $2.6B | (3.70%) |
| FY2018 | $2.7B | (2.51%) |
| FY2017 | $2.7B | (1.40%) |
| FY2016 | $2.8B | (1.90%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $2.5B | 0.32% |
| Jun 2026 | $2.5B | (0.08%) |
| Mar 2026 | $2.5B | (1.40%) |
| Dec 2025 | $2.5B | 0.36% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.8B |
| NVO Novo Nordisk A/S compare | $4.4B |
| MRK Merck & Co., Inc. | $2.5B |
| JNJ Johnson & Johnson compare | $2.4B |
| NVS Novartis AG compare | $1.9B |
| ABBV AbbVie Inc. compare | $1.8B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.3B |
| AMGN Amgen Inc. compare | $546.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement